TREAKISYM® Indication Expansion and Domestic Approval Acquisition
A program to pursue domestic approval applications and PMDA consultations for multiple additional indications for TREAKISYM®, with the aim of obtaining approvals including bendamustine-rituximab (BR) therapy for r/r DLBCL.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.